Gut bacterial aggregates as living gels

  1. Brandon H Schlomann
  2. Raghuveer Parthasarathy  Is a corresponding author
  1. University of Oregon, United States

Abstract

The spatial organization of gut microbiota influences both microbial abundances and host-microbe interactions, but the underlying rules relating bacterial dynamics to large-scale structure remain unclear. To this end we studied experimentally and theoretically the formation of three-dimensional bacterial clusters, a key parameter controlling susceptibility to intestinal transport and access to the epithelium. Inspired by models of structure formation in soft materials, we sought to understand how the distribution of gut bacterial cluster sizes emerges from bacterial-scale kinetics. Analyzing imaging-derived data on cluster sizes for eight different bacterial strains in the larval zebrafish gut, we find a common family of size distributions that decay approximately as power laws with exponents close to -2, becoming shallower for large clusters in a strain-dependent manner. We show that this type of distribution arises naturally from a Yule-Simons-type process in which bacteria grow within clusters and can escape from them, coupled to an aggregation process that tends to condense the system toward a single massive cluster, reminiscent of gel formation. Together, these results point to the existence of general, biophysical principles governing the spatial organization of the gut microbiome that may be useful for inferring fast-timescale dynamics that are experimentally inaccessible.

Data availability

A table of all bacterial cluster sizes analysed in this study is included in the Supplementary Data File. MATLAB code for simulating the models described in the study is available at https://github.com/rplab/cluster_kinetics

The following previously published data sets were used

Article and author information

Author details

  1. Brandon H Schlomann

    University of Oregon, Eugene, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Raghuveer Parthasarathy

    University of Oregon, Eugene, United States
    For correspondence
    raghu@uoregon.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6006-4749

Funding

National Institutes of Health (P50GM09891)

  • Brandon H Schlomann
  • Raghuveer Parthasarathy

National Institutes of Health (P01GM125576)

  • Brandon H Schlomann
  • Raghuveer Parthasarathy

National Institutes of Health (F32AI112094)

  • Brandon H Schlomann
  • Raghuveer Parthasarathy

National Institutes of Health (T32GM007759)

  • Raghuveer Parthasarathy

National Science Foundation (1427957)

  • Brandon H Schlomann
  • Raghuveer Parthasarathy

James S. McDonnell Foundation

  • Brandon H Schlomann

Kavli Foundation (Kavli Microbiome Ideas Challenge)

  • Brandon H Schlomann
  • Raghuveer Parthasarathy

National Institutes of Health (P01HD22486)

  • Brandon H Schlomann
  • Raghuveer Parthasarathy

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The studies that generated the data analyzed in this paper (see cited references) were done in strict accordance with protocols approved by the University of Oregon Institutional Animal Care and Use Committee and following standard protocols.

Reviewing Editor

  1. Kevin B Wood, University of Michigan, United States

Publication history

  1. Preprint posted: June 8, 2021 (view preprint)
  2. Received: June 9, 2021
  3. Accepted: September 6, 2021
  4. Accepted Manuscript published: September 7, 2021 (version 1)
  5. Version of Record published: October 13, 2021 (version 2)
  6. Version of Record updated: October 22, 2021 (version 3)
  7. Version of Record updated: October 25, 2021 (version 4)

Copyright

© 2021, Schlomann & Parthasarathy

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,135
    Page views
  • 161
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Brandon H Schlomann
  2. Raghuveer Parthasarathy
(2021)
Gut bacterial aggregates as living gels
eLife 10:e71105.
https://doi.org/10.7554/eLife.71105

Further reading

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Liselot Dewachter et al.
    Research Article

    Antibiotic resistance in the important opportunistic human pathogen Streptococcus pneumoniae is on the rise. This is particularly problematic in the case of the β-lactam antibiotic amoxicillin, which is the first-line therapy. It is therefore crucial to uncover targets that would kill or resensitize amoxicillin-resistant pneumococci. To do so, we developed a genome-wide, single-cell based, gene silencing screen using CRISPR interference called sCRilecs-seq (subsets of CRISPR interference libraries extracted by fluorescence activated cell sorting coupled to next generation sequencing). Since amoxicillin affects growth and division, sCRilecs-seq was used to identify targets that are responsible for maintaining proper cell size. Our screen revealed that downregulation of the mevalonate pathway leads to extensive cell elongation. Further investigation into this phenotype indicates that it is caused by a reduced availability of cell wall precursors at the site of cell wall synthesis due to a limitation in the production of undecaprenyl phosphate (Und-P), the lipid carrier that is responsible for transporting these precursors across the cell membrane. The data suggest that, whereas peptidoglycan synthesis continues even with reduced Und-P levels, cell constriction is specifically halted. We successfully exploited this knowledge to create a combination treatment strategy where the FDA-approved drug clomiphene, an inhibitor of Und-P synthesis, is paired up with amoxicillin. Our results show that clomiphene potentiates the antimicrobial activity of amoxicillin and that combination therapy resensitizes amoxicillin-resistant S. pneumoniae. These findings could provide a starting point to develop a solution for the increasing amount of hard-to-treat amoxicillin-resistant pneumococcal infections.

    1. Microbiology and Infectious Disease
    Dallas L Mould et al.
    Research Article Updated

    Microbes frequently evolve in reproducible ways. Here, we show that differences in specific metabolic regulation rather than inter-strain interactions explain the frequent presence of lasR loss-of-function (LOF) mutations in the bacterial pathogen Pseudomonas aeruginosa. While LasR contributes to virulence through its role in quorum sensing, lasR mutants have been associated with more severe disease. A model based on the intrinsic growth kinetics for a wild type strain and its LasR derivative, in combination with an experimental evolution based genetic screen and further genetics analyses, indicated that differences in metabolism were sufficient to explain the rise of these common mutant types. The evolution of LasR lineages in laboratory and clinical isolates depended on activity of the two-component system CbrAB, which modulates substrate prioritization through the catabolite repression control pathway. LasR lineages frequently arise in cystic fibrosis lung infections and their detection correlates with disease severity. Our analysis of bronchoalveolar lavage fluid metabolomes identified compounds that negatively correlate with lung function, and we show that these compounds support enhanced growth of LasR cells in a CbrB-controlled manner. We propose that in vivo metabolomes contribute to pathogen evolution, which may influence the progression of disease and its treatment.